What Happened

UK BioTech Thalia Therapeutics acquired Sanmirna Therapeutics for €4.2M upfront (€15M potential milestones) and separately raised €3.1M. The deal brings miRisten, a Phase 1 microRNA therapy targeting Acute Myeloid Leukaemia (AML), into Thalia's pipeline.

Who Is Affected

Thalia's shareholders gain exposure to clinical-stage assets. Sanmirna's team joins Thalia. Competitors include STORM Therapeutics (€47.5M raised) and Engitix (€21M). AML researchers and RNA therapeutics vendors should note accelerated timelines.

Market Impact

• Validates RNA therapeutics in oncology with €111.5M+ in comparable 2026 EU funding
• AML market potential: $3.9B globally
• Thalia now has 3 clinical assets (miRisten, Nuvec, cardiovascular)

What to Watch

miRisten Phase 1 topline results expected H1 2027. Monitor Thalia's integration of Sanmirna's team and tech. Track milestone payments triggering additional €15M payout.